文献速递基础与转化研究临床试验与 GCP

AAV5-hFVIII-SQ基因治疗血友病A的多年度随访

Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.
PubMed 文献 · N Engl J Med · 2020-01-01

该研究对15例重型血友病A成人患者单次输注不同剂量AAV5-hFVIII-SQ后随访长达3年,评估因子VIII表达、年化出血率、外源性因子VIII使用及安全性。结果显示高剂量组(4×10^13或6×10^13 vg/kg)患者因子VIII表达中位数分别为13或20 IU/dl,年化治疗出血事件中位数为0,外源性因子VIII使用从每年138.5或155.5次输注降至0或0.5次,未发生抑制剂、血栓、死亡或肝功能持续异常。

要点

  • 高剂量组(4×10^13或6×10^13 vg/kg)患者年化出血事件中位数为0,外源性因子VIII使用近乎停止。
  • 未观察到抑制剂开发、血栓形成、死亡或肝功能持续改变。
  • 低剂量组(6×10^12或2×10^13 vg/kg)因子VIII表达低于1 IU/dl。

核心结论

  • AAV5-hFVIII-SQ基因治疗在血友病A患者中产生持续、有临床意义的获益,高剂量组出血率大幅降低且完全停止预防性因子VIII使用。

研究设计与样本

  • 报告15例重型血友病A成人(因子VIII≤1 IU/dl)单次输注不同剂量AAV5-hFVIII-SQ后长达3年的随访结果。
  • 评估因子VIII水平、年化出血事件率、因子VIII使用、安全性、表达动力学及AAV转导的生物标志物。

主要发现

  • 输注3年后,2例(分别接受6×10^12 vg/kg和2×10^13 vg/kg)因子VIII表达低于1 IU/dl(显色法)。
  • 7例接受6×10^13 vg/kg者因子VIII表达中位数20 IU/dl,年化治疗出血事件中位数0,外源性因子VIII使用中位数从每年138.5次输注降至0次。
  • 该队列所有靶关节出血缓解(12个月内≤2次出血事件)。
  • 输注2年后,6例接受4×10^13 vg/kg者因子VIII表达中位数13 IU/dl,年化出血事件率中位数0,因子VIII使用中位数从每年155.5次输注降至0.5次。
  • 6例中5例靶关节出血缓解;未观察到抑制剂开发、血栓、死亡或肝功能持续改变。

临床怎么用

  • 高剂量AAV5-hFVIII-SQ基因治疗可能使重型血友病A患者停止预防性因子VIII输注并维持低出血率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adeno-associated virus (AAV)-mediated gene therapy is under investigation as a therapeutic option for persons with hemophilia A. Efficacy and safety data include 3 years of follow-up after a single administration of AAV5-hFVIII-SQ. METHODS: We report durable efficacy, long-term safety, and clinical and biologic results in 15 adults with severe hemophilia A (factor VIII level, ≤1 IU per deciliter) who had received a single infusion of AAV5-hFVIII-SQ at various dose levels. We evaluated the factor VIII level, annualized rate of bleeding events, use of factor VIII, safety, expression kinetics, and biologic markers of AAV transduction for up to 3 years. RESULTS: Three years after infusion, two participants (one who had received 6×1012 vector genomes [vg] per kilogram of body weight and one who had received 2×1013 vg per kilogram) had factor VIII expression of less than 1 IU per deciliter, as assessed on chromogenic assay. Seven participants (who had received 6×1013 vg per kilogram) had a median factor VIII expression of 20 IU per deciliter; the median number of annualized treated bleeding events was 0, and the median use of exogenous factor VIII was reduced from 138.5 infusions to 0 infusions per year. Bleeding in all target joints (major joints with ≥3 bleeding events within 6 months) in this cohort resolved (≤2 bleeding events within 12 months). Two years after infusion, six participants (who had received 4×1013 vg per kilogram) had a median factor VIII expression of 13 IU per deciliter; the median annualized rate of bleeding events was 0, and the median use of factor VIII was reduced from 155.5 infusions to 0.5 infusions per year. Bleeding in target joints resolved in five of six participants. The factor VIII pharmacodynamic profiles reflected cellular turnover in the blood and molecular events leading to episomal DNA stabilization for persistent expression, findings that are consistent with previous observations in two model systems. Transgene-derived human factor VIII (hFVIII) protein activity mirrored native hFVIII in hemostatic ability. No inhibitor development, thromboses, deaths, or persistent changes in liver-function tests were observed. CONCLUSIONS: Gene therapy with AAV5-hFVIII-SQ vector in participants with hemophilia A resulted in sustained, clinically relevant benefit, as measured by a substantial reduction in annualized rates of bleeding events and complete cessation of prophylactic factor VIII use in all participants who had received 4×1013 vg per kilogram or 6×1013 vg per kilogram of the gene therapy. (Funded by BioMarin Pharmaceutical; ClinicalTrials.gov number, NCT02576795; EudraCT number, 2014-003880-38.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Pasi KJ, Rangarajan S, Mitchell N, et al. Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A. N Engl J Med. 2020. PMID: 31893514. doi:10.1056/NEJMoa1908490

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。